anti tim-3/cd123 car-t cell therapy
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 4, 2023 (NCT06125652)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
- Hepatitis A virus cellular receptor 2Immunity, passive
immunity, passive - TIM3
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06125652 | Phase 1/Phase 2 (Phase 2) | Nov 4, 2023 | Xuzhou Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xuzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
1 organizations
Page 1 / 1